利鲁唑-三唑杂合物作为肌萎缩侧索硬化症神经保护的新型化学探针。
Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.
作者信息
Sweeney Joseph B, Rattray Marcus, Pugh Victoria, Powell Lucy A
机构信息
Department of Chemistry, Lancaster University, Lancaster LA1 4YB, U.K.
School of Pharmacy and Medical Sciences, University of Bradford, Bradford BD7 1DP, U.K.
出版信息
ACS Med Chem Lett. 2018 May 30;9(6):552-556. doi: 10.1021/acsmedchemlett.8b00103. eCollection 2018 Jun 14.
Abstract
Despite intense attention from biomedical and chemical researchers, there are few approved treatments for amyotrophic lateral sclerosis (ALS), with only riluzole (Rilutek) and edaravone (Radicava) currently available to patients. Moreover, the mechanistic basis of the activity of these drugs is currently not well-defined, limiting the ability to design new medicines for ALS. This Letter describes the synthesis of triazole-containing riluzole analogues, and their testing in a novel neuroprotective assay. Seven compounds were identified as having neuroprotective activity, with two compounds having similar activity to riluzole.
摘要
尽管生物医学和化学研究人员给予了高度关注，但目前针对肌萎缩侧索硬化症（ALS）的获批治疗方法很少，患者目前仅能使用利鲁唑（力如太）和依达拉奉（瑞必乐）。此外，这些药物活性的作用机制目前尚不清楚，这限制了设计治疗ALS新药的能力。本信函描述了含三唑的利鲁唑类似物的合成及其在一种新型神经保护试验中的测试。七种化合物被鉴定具有神经保护活性，其中两种化合物具有与利鲁唑相似的活性。
相似文献
1
Riluzole-Triazole Hybrids as Novel Chemical Probes for Neuroprotection in Amyotrophic Lateral Sclerosis.利鲁唑-三唑杂合物作为肌萎缩侧索硬化症神经保护的新型化学探针。
ACS Med Chem Lett. 2018 May 30;9(6):552-556. doi: 10.1021/acsmedchemlett.8b00103. eCollection 2018 Jun 14.
2
Riluzole and edaravone: A tale of two amyotrophic lateral sclerosis drugs.力如太与依达拉奉：两种肌萎缩侧索硬化症药物的故事。
Med Res Rev. 2019 Mar;39(2):733-748. doi: 10.1002/med.21528. Epub 2018 Aug 12.
3
New Adamantane-Containing Edaravone Conjugates as Potential Neuroprotective Agents for ALS Treatments.新型含金刚烷的依达拉奉缀合物作为肌萎缩侧索硬化症治疗的潜在神经保护剂
Molecules. 2023 Nov 13;28(22):7567. doi: 10.3390/molecules28227567.
4
Edaravone: a new hope for deadly amyotrophic lateral sclerosis.依达拉奉：治疗致命性肌萎缩侧索硬化症的新希望。
Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189.
5
Two Decades-Long Journey from Riluzole to Edaravone: Revisiting the Clinical Pharmacokinetics of the Only Two Amyotrophic Lateral Sclerosis Therapeutics.从利鲁唑到依达拉奉：二十年的历程——重新审视唯二两种肌萎缩侧索硬化症治疗药物的临床药代动力学。
Clin Pharmacokinet. 2018 Nov;57(11):1385-1398. doi: 10.1007/s40262-018-0655-4.
6
Tofersen (Qalsody) for ALS.用于治疗肌萎缩侧索硬化症的托非生（Qalsody）。
Med Lett Drugs Ther. 2023 Jul 24;65(1681):113-114. doi: 10.58347/tml.2023.1681a.
7
Effect of riluzole (Rilutek) treatment on plasma amino acid percentages in amyotrophic lateral sclerosis patients.利鲁唑（力如太）治疗对肌萎缩侧索硬化症患者血浆氨基酸百分比的影响。
Neurol Sci. 2003 Nov;24(4):290-2. doi: 10.1007/s10072-003-0160-9.
8
Riluzole, neuroprotection and amyotrophic lateral sclerosis.利鲁唑、神经保护和肌萎缩侧索硬化症。
Curr Med Chem. 2010;17(18):1942-199. doi: 10.2174/092986710791163939.
9
Biological aspects of nitrogen heterocycles for amyotrophic lateral sclerosis.氮杂环化合物在肌萎缩侧索硬化症中的生物学特性
Appl Microbiol Biotechnol. 2023 Jan;107(1):43-56. doi: 10.1007/s00253-022-12317-y. Epub 2022 Dec 8.
10
Novel therapies in development that inhibit motor neuron hyperexcitability in amyotrophic lateral sclerosis.正在研发的用于抑制肌萎缩侧索硬化症中运动神经元过度兴奋的新型疗法。
Expert Rev Neurother. 2016 Oct;16(10):1147-54. doi: 10.1080/14737175.2016.1197774. Epub 2016 Jun 17.
引用本文的文献
1
Targeting Neurodegeneration: The Emerging Role of Hybrid Drugs.靶向神经退行性变：混合型药物的新作用
Curr Drug Targets. 2025;26(6):410-434. doi: 10.2174/0113894501365588250131073304.
2
Riluzole-Rasagiline Hybrids: Toward the Development of Multi-Target-Directed Ligands for Amyotrophic Lateral Sclerosis.利鲁唑-雷沙吉兰杂合体：开发用于肌萎缩侧索硬化症的多靶标导向配体。
ACS Chem Neurosci. 2022 Aug 3;13(15):2252-2260. doi: 10.1021/acschemneuro.2c00261. Epub 2022 Jul 22.
3
DMSO-mediated palladium-catalyzed cyclization of two isothiocyanates C-H sulfurization: a new route to 2-aminobenzothiazoles.二甲基亚砜介导的两种异硫氰酸酯的钯催化环化反应：C-H硫化反应——一种合成2-氨基苯并噻唑的新途径。
RSC Adv. 2019 Jan 25;9(6):3403-3406. doi: 10.1039/c8ra09784d. eCollection 2019 Jan 22.
4
From Riluzole to Dexpramipexole via Substituted-Benzothiazole Derivatives for Amyotrophic Lateral Sclerosis Disease Treatment: Case Studies.从利鲁唑到通过取代苯并噻唑衍生物治疗肌萎缩侧索硬化症：案例研究。
Molecules. 2020 Jul 22;25(15):3320. doi: 10.3390/molecules25153320.
5
Molecular Hybridization as a Tool in the Design of Multi-target Directed Drug Candidates for Neurodegenerative Diseases.分子杂交作为设计针对神经退行性疾病的多靶标导向药物候选物的工具。
Curr Neuropharmacol. 2020;18(5):348-407. doi: 10.2174/1385272823666191021124443.
6
1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.含 1,2,3-三唑的杂合体作为药物化学中的先导化合物：最新概述。
Bioorg Med Chem. 2019 Aug 15;27(16):3511-3531. doi: 10.1016/j.bmc.2019.07.005. Epub 2019 Jul 4.
7
Hydrogen-bonded mol-ecular salts of reduced benzo-thia-zole derivatives with carboxyl-ates: a robust (8) supra-molecular motif (even when disordered).还原苯并噻唑衍生物与羧酸盐形成的氢键分子盐：一种稳定的（8）超分子基序（即使存在无序情况）。
Acta Crystallogr E Crystallogr Commun. 2019 Jan 8;75(Pt 2):167-174. doi: 10.1107/S2056989018018224. eCollection 2019 Feb 1.
本文引用的文献
1
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive ALS.随机、双盲、安慰剂对照试验中使用盐酸氨氯地平治疗快速进展性肌萎缩侧索硬化症。
Neurology. 2018 Feb 13;90(7):e565-e574. doi: 10.1212/WNL.0000000000004960. Epub 2018 Jan 24.
2
Motor neuron disease in 2017: Progress towards therapy in motor neuron disease.2017年的运动神经元病：运动神经元病治疗进展
Nat Rev Neurol. 2018 Feb;14(2):65-66. doi: 10.1038/nrneurol.2017.186. Epub 2018 Jan 19.
3
Potent and Selective EphA4 Agonists for the Treatment of ALS.用于治疗肌萎缩侧索硬化症的强效且选择性的EphA4激动剂。
Cell Chem Biol. 2017 Mar 16;24(3):293-305. doi: 10.1016/j.chembiol.2017.01.006. Epub 2017 Feb 9.
4
Role of the Sigma-1 receptor in Amyotrophic Lateral Sclerosis (ALS).σ-1受体在肌萎缩侧索硬化症（ALS）中的作用。
J Pharmacol Sci. 2015 Jan;127(1):10-6. doi: 10.1016/j.jphs.2014.12.013. Epub 2015 Jan 5.
5
Treatment of amyotrophic lateral sclerosis: lessons learned from many failures.肌萎缩侧索硬化症的治疗：从诸多失败中吸取的教训
ACS Med Chem Lett. 2014 Oct 8;5(11):1179-81. doi: 10.1021/ml500404b. eCollection 2014 Nov 13.
6
Assessing social isolation in motor neurone disease: a Rasch analysis of the MND Social Withdrawal Scale.评估肌萎缩侧索硬化症中的社交孤立：MND 社交回避量表的 Rasch 分析。
J Neurol Sci. 2013 Nov 15;334(1-2):112-8. doi: 10.1016/j.jns.2013.08.002. Epub 2013 Aug 9.
7
In silico docking reveals possible Riluzole binding sites on Nav1.6 sodium channel: implications for amyotrophic lateral sclerosis therapy.计算机对接揭示了 Nav1.6 钠离子通道上可能的利鲁唑结合位点：对肌萎缩侧索硬化症治疗的影响。
J Theor Biol. 2012 Dec 21;315:53-63. doi: 10.1016/j.jtbi.2012.09.004. Epub 2012 Sep 18.
8
Amyotrophic lateral sclerosis.肌萎缩性侧索硬化症。
Lancet. 2011 Mar 12;377(9769):942-55. doi: 10.1016/S0140-6736(10)61156-7. Epub 2011 Feb 4.
9
Tumour necrosis factor alpha induces rapid reduction in AMPA receptor-mediated calcium entry in motor neurones by increasing cell surface expression of the GluR2 subunit: relevance to neurodegeneration.肿瘤坏死因子-α通过增加谷氨酸受体 2 亚基的细胞表面表达，诱导运动神经元中 AMPA 受体介导的钙内流的快速减少：与神经退行性变有关。
J Neurochem. 2010 May;113(3):692-703. doi: 10.1111/j.1471-4159.2010.06634.x. Epub 2010 Feb 1.
10
Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study.英国运动神经元病的发病率及终生风险：一项基于人群的研究。
Eur J Neurol. 2009 Jun;16(6):745-51. doi: 10.1111/j.1468-1331.2009.02586.x.
Zotero 插件